Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
12,176 total articles
Goldberg Chen, CoreWeave's executive vice president of product and engineering, sold 9,757 shares of Class A common stock on April 8, 2026, generating $897,644. The transaction was carried out under a Rule 10b5-1 trading plan established June 3, 2025 and modified November 20, 2025. Following the sale, Chen holds 48,946 shares. Separately, CoreWeave…
CoreWeave CEO Michael N Intrator sold 52,599 shares of Class A common stock on April 8, 2026, in a series of transactions that generated $5,567,082. The trades were carried out under a Rule 10b5-1 plan adopted last November. The company has recently announced multiple large agreements and financing moves, including a multi-year Anthropic compute de…
CoreWeave Chief Financial Officer Nitin Agrawal sold 14 shares of Class A common stock for $1,288 on April 8, 2026 under a Rule 10b5-1 plan. The transaction comes as the company expands a Meta contract by $21 billion, increases convertible note issuance to $3.5 billion, and signs a multi-year infrastructure agreement with Anthropic. Equity ratings …
Vernon Rogers, AEHR Test Systems' Executive Vice President of Sales & Marketing, sold 10,888 shares on April 10, 2026, for $70.00 per share, totaling $762,160. The company reported third-quarter fiscal 2026 results with an EPS of -$0.05 beating expectations while revenue of $10.3 million missed forecasts; bookings were strong at $37.2 million with …
Adil Engineer, Chief Operating Officer of Aehr Test Systems (NASDAQ: AEHR), sold 13,085 shares on April 9, 2026, for about $892,182 and exercised options to buy 10,582 shares at $9.45. The company reported mixed fiscal third-quarter results with an EPS beat but revenue shortfall and robust bookings, while analysts have reacted by raising price targ…
Rhea J. Posedel, a director at Aehr Test Systems (NASDAQ: AEHR), sold 30,000 common shares on April 9, 2026, for $70 per share, totaling $2.1 million. The trade took place while the stock was trading close to its 52-week high of $72.50. Following the sale, Posedel retains direct ownership of 71,163 shares, inclusive of unvested restricted stock uni…
Aehr Test Systems Chief Technology Officer Donald P. Richmond II executed a sale of 15,751 shares on April 9, 2026, generating roughly $1.08 million. The transaction occurred while the share price is trading near a 52-week high amid a year-over-year surge. Separately, the company released mixed fiscal third-quarter results that included stronger-th…
Laura Oliphant, a director at Aehr Test Systems (NASDAQ: AEHR), sold 3,000 shares on April 9, 2026, for $68.3575 each, generating proceeds of $205,072. The transaction occurred while the share price sits close to its 52-week high of $72.50 after a 727% gain over the past year. Following the sale Oliphant maintains direct and indirect holdings total…
Director Scott Geoffrey Gates sold 35,000 Aehr Test Systems shares on April 9, 2026, generating about $2.37 million in proceeds. The transactions, executed at prices between $67.75 and $68, occurred while the stock traded close to its 52-week high of $72.50 after a dramatic 727% gain over the prior year. The company reported mixed fiscal third-quar…
Naixi Wu, chief financial officer of indie Semiconductor, executed sales of 55,000 Class A common shares on April 9, 2026, generating roughly $154,560 in proceeds through two transactions. The filings show Wu also exercised 100,000 option-related restricted stock units on April 8, 2026. The trades were carried out under a Rule 10b5-1 plan adopted i…
Apogee Therapeutics Chief Executive Officer Michael Thomas Henderson sold 20,000 shares of common stock on April 8, 2026, for roughly $1.65 million under a previously adopted Rule 10b5-1 plan. The sales were executed in three transactions at prices between $82.48 and $85.00, as the stock trades close to its 52-week high after a 171% gain over the p…
Spire Global Inc.'s Chief Technology Officer, Johann Gabriel Oehme, reported a sale of 12,757 Class A shares on February 20, 2026, for $108,817. The company has seen its stock climb sharply since that sale and is pursuing a roughly $70 million private placement while expanding satellite-based data products and participating in a geomagnetic measure…
Framework Ventures IV L.P. purchased 54,384 shares of Better Home & Finance Holding Co at $32.96 per share on April 10, 2026, a transaction valued at $1,792,496. The firm now directly holds 1,006,696 shares. The purchase coincides with company disclosures of a robust preliminary Q1 2026 funded loan volume of $1.64 billion, a priced follow-on offeri…
Fermi Inc. Chief Financial Officer Miles E. Everson sold 830,209 shares of common stock on April 8 and April 9, 2026, generating roughly $3.9 million in proceeds. The trades occurred as Fermi shares trade near a 52-week low after an 85% year-over-year decline. Recent quarterly results from Fermi America LLC showed a substantial net loss and elevate…
Charles Lynn Hamilton, Chief Site Development Officer at Fermi Inc (NASDAQ: FRMI), sold 774,090 shares of common stock on April 8 and 9, 2026, for proceeds totaling $3,669,395. The transactions occurred as Fermi's shares traded near a 52-week low and followed the disclosure of fourth-quarter 2025 results showing a sizable net loss and elevated non-…
Fermi Inc. Chief Operating Officer Jacobo Ortiz Blanes sold 830,908 common shares on April 8 and April 9, 2026, for roughly $3.9 million, according to an SEC Form 4. The transactions leave Ortiz Blanes with 5,469,092 directly held shares and a potential beneficial interest in 7,875,000 shares held by an entity he manages. The insider moves come as …
Peter Platzer, Executive Chairman of Spire Global, sold $1,884,577 in Class A common shares through a sequence of transactions recorded between May 20, 2024, and January 21, 2026, according to a Form 4 filing. The trades, executed under transaction code "S," were carried out to satisfy tax obligations tied to restricted stock unit settlements. The …
Spire Global CEO Theresa Condor disposed of 105,667 Class A shares between May 20, 2024 and January 21, 2026 under pre-scheduled sale-to-cover instructions, generating $1,126,487 in gross proceeds. The sales coincided with a sharp run-up in SPIR shares, while the company is pursuing a roughly $70 million private placement and rolling out new data p…
Kevin J. McCallion, senior vice president of Products and Production at 908 Devices Inc. (MASS), exercised options to purchase 24,000 shares and sold those same shares on April 8 and 9, 2026, for roughly $169,091. The transactions occurred as the company reported better-than-expected fourth-quarter 2025 results and received a reaffirmed Buy rating …
Photronics Inc. Chief Executive George Macricostas reported the sale of 120,194 shares on April 8, 2026, in a Form 4 filing, generating $5,203,717. The transactions occurred in three tranches at prices between $42.90 and $43.28. The company recently reported fiscal Q1 2026 results that beat analyst estimates and announced a new mask writer to be in…
Velaga S. Ram, president of Broadcom’s Infrastructure Software Group, reported the sale of 30,215 Broadcom shares across two transactions on April 8 and April 9, 2026, totaling $10,638,012. The disclosures arrive amid several company announcements including a new machine learning fraud-detection product and expanded TPU partnerships with Google and…
Adaptive Biotechnologies NASDAQ:ADPT Chief People Officer Francis Lo sold 22,564 shares on April 8, 2026, under a Rule 10b5-1 plan for roughly $340,039, and exercised options to acquire 2,344 shares the same day. The company’s shares have declined since the sale and InvestingPro flags the stock as appearing overvalued versus its Fair Value estimate…
Adaptive Biotechnologies Chief Scientific Officer Harlan S. Robins sold 10,000 shares of common stock on April 8, 2026, for total proceeds of $148,500. The disposals, executed in multiple tranches under a Rule 10b5-1 trading plan adopted in August 2025, occurred at prices between $14.65 and $15.06. After the transactions Robins holds 1,512,058 shar…
Whitehawk Therapeutics Chief Executive Officer David James Lennon sold 14,500 shares of common stock on April 9, 2026, for $3.38 per share, netting $49,010. The sale, disclosed on a Form 4 filing, was executed to meet tax withholding obligations tied to vesting restricted stock units. Separately, the company presented research showing elevated and …
Director Christopher D. Brown sold a combined $282,277 of 908 Devices Inc. (MASS) stock across three trades between April 8 and April 10, 2026. The disposals were made under a Rule 10b5-1 trading plan adopted in November 2025. The company recently reported fourth-quarter 2025 results that beat expectations on both EPS and revenue, and an analyst at…
